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Loss of c-Jun N-terminal Kinase 1 and 2 
Function in Liver Epithelial Cells Triggers 
Biliary Hyperproliferation Resembling 
Cholangiocarcinoma
Francisco Javier Cubero ,1-3* Mohamed Ramadan Mohamed,1,4* Marius M. Woitok,1 Gang Zhao,1 Maximilian Hatting,1  
Yulia A. Nevzorova,1,5 Chaobo Chen ,2 Johannes Haybaeck,6-8 Alain de Bruin,9,10 Matias A. Avila ,11-13  
Mark V. Boekschoten,14 Roger J. Davis,15 and Christian Trautwein1
Targeted inhibition of the c-Jun N-terminal kinases ( JNKs) has shown therapeutic potential in intrahepatic cholan-
giocarcinoma (CCA)-related tumorigenesis. However, the cell-type-specific role and mechanisms triggered by JNK in 
liver parenchymal cells during CCA remain largely unknown. Here, we aimed to investigate the relevance of JNK1 
and JNK2 function in hepatocytes in two different models of experimental carcinogenesis, the dethylnitrosamine 
(DEN) model and in nuclear factor kappa B essential modulator (NEMO)hepatocyte-specific knockout (Δhepa) mice, focusing 
on liver damage, cell death, compensatory proliferation, fibrogenesis, and tumor development. Moreover, regulation of 
essential genes was assessed by reverse transcription polymerase chain reaction, immunoblottings, and immunostain-
ings. Additionally, specific Jnk2 inhibition in hepatocytes of NEMOΔhepa/JNK1Δhepa mice was performed using small 
interfering (si) RNA (siJnk2) nanodelivery. Finally, active signaling pathways were blocked using specific inhibitors. 
Compound deletion of Jnk1 and Jnk2 in hepatocytes diminished hepatocellular carcinoma (HCC) in both the DEN 
model and in NEMOΔhepa mice but in contrast caused massive proliferation of the biliary ducts. Indeed, Jnk1/2 de-
ficiency in hepatocytes of NEMOΔhepa (NEMOΔhepa/JNKΔhepa) animals caused elevated fibrosis, increased apoptosis, 
increased compensatory proliferation, and elevated inflammatory cytokines expression but reduced HCC. Furthermore, 
siJnk2 treatment in NEMOΔhepa/JNK1Δhepa mice recapitulated the phenotype of NEMOΔhepa/JNKΔhepa mice. Next, we 
sought to investigate the impact of molecular pathways in response to compound JNK deficiency in NEMOΔhepa mice. 
We found that NEMOΔhepa/JNKΔhepa livers exhibited overexpression of the interleukin-6/signal transducer and activator 
of transcription 3 pathway in addition to epidermal growth factor receptor (EGFR)-rapidly accelerated fibrosarcoma 
(Raf )-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade. The func-
tional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic on-
cogene B-2 (ErbB2) and EGFR signaling, to NEMOΔhepa/JNKΔhepa mice. Lapatinib effectively inhibited cystogenesis, 
improved transaminases, and effectively blocked EGFR-Raf-MEK-ERK signaling. Conclusion: We define a novel func-
tion of JNK1/2 in cholangiocyte hyperproliferation. This opens new therapeutic avenues devised to inhibit pathways of 
cholangiocarcinogenesis. (Hepatology Communications 2020;4:834-851).
Bile duct hyperplasia and aberrant cholangiocyte growth can result in hepatic cystogenesis, differ-entially diagnosed on the basis of cholangioma, 
cholangiofibrosis, intrahepatic cholangiocarcinoma 
(CCA), and oval cell hyperplasia.(1,2) CCA, a malig-
nancy that arises in the setting of chronic inflam-
mation of biliary epithelium cells, has an increasing 
incidence and is the second most common primary 
Abbreviations: α-SMA, alpha smooth muscle actin; Δhepa, hepatocyte-specif ic knockout; A6, Notch-1; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; BW, body weight; CAF, cancer-associated f ibroblast; CC3, cleaved caspase 3; CCA, cholangiocarcinoma; CK, creatine 
kinase; CLD, chronic liver disease; Col1A1, collagen type I alpha 1; DEN, diethylnitrosamine; dmbt1, deleted in malignant brain tumors 1; 
ECM, extracellular matrix; EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal transition; ERBB, erythroblastic oncogene B; 
ERK, extracellular signal-regulated kinase; f/f, floxed mice; gabrp, gamma-aminobutyric acid A receptor, pi; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; HCC, hepatocellular carcinoma; HER, human epidermal growth factor receptor; HNF, hepatocyte nuclear factor; HPF, high-power 
f ield; IHC, immunohistochemistry; IL, interleukin; JAK, Janus kinase; JNK, c-Jun N-terminal kinases; LoxP, locus of X-over P1; LPC, liver 
parenchymal cell; LW, liver weight; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; mRNA, messenger 
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liver cancer globally. Unfortunately, survival beyond 
a year of diagnosis is less than 5% and therapeutic 
options are scarce.(3)
Several in vivo and in vitro models as well as research 
with human tissue samples help to elucidate the main 
pathways implicated in CCA formation. However, 
none of these studies recapitulates the human disease, 
and translation into improved patient outcome has 
not been achieved. In addition, the pathophysiology 
of CCA remains poorly understood. Thus, there is an 
urgent need for new models to improve the manage-
ment of this insidious and devastating disease.
RNA; MUC, mucin; NEMO, nuclear factor kappa B essential modulator; NF-κB, nuclear factor kappa B; OSM, oncostatin M; p, phosphorylated; 
PCNA, proliferating cell nuclear antigen; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; Raf, rapidly accelerated 
f ibrosarcoma; RIPK, receptor-interacting serine/threonine-protein kinase; si, small interfering; SOCS3, suppressor of cytokine signaling 3; SOX-
9, transcription factor SOX 9; STAT, signal transducer and activator of transcription; TKI, tyrosine kinase inhibitor; TNF, tumor necrosis factor; 
TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling.
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The c-Jun N-terminal kinases ( JNKs) are evolu-
tionarily conserved mitogen-activated protein kinases 
(MAPKs) and play an important role in convert-
ing extracellular stimuli into a wide range of cellu-
lar responses, including inflammatory response, stress 
response, differentiation, and survival.(4) In tumorigen-
esis, JNK has been shown to have tumor suppressive 
function in breast,(5) prostate,(6) lung,(7) and pancreas(8) 
cancer. However, the pro-oncogenic role for JNK has 
also been well documented.(9-11) Importantly, JNK has 
lineage-determinant functions in liver parenchymal cells 
(LPCs) where it not only favors proliferation of biliary 
cells but also directly biases biliary cell-fate decisions in 
bipotential hepatic cells. It has been reported that JNK 
inhibition delays CCA progression(12) by impeding 
JNK-mediating biliary proliferation. These data indicate 
that JNK modulation would be of therapeutic benefit in 
patients with CCA. Nevertheless, little is known about 
the cell-type-specific role and mechanism of JNK in 
biliary overgrowth in order to have a targeted and defi-
nite therapy against CCA.
In the present study, we investigated the implications 
of hepatocyte-defective JNK signaling in experimental 
carcinogenesis. Unexpectedly, loss of Jnk1/2 in LPCs 
inhibited hepatocellular carcinoma (HCC) but trig-
gered biliary epithelium hyperproliferation and features 
compatible with CCA. Overall, our data uniformly sug-
gest that hepatocytic JNK is pivotal for biliary epithelial 
hyperproliferation resulting in ducto/cystogenesis.
Materials and Methods
geneRation oF miCe anD 
animal eXpeRiments
Albumin (Alb)-Cre and Jnk2-deficient mice 
in a C57BL/6J background were purchased from 
the Jackson Laboratory (Bar Harbor, ME). 
Jnk1locus of X-over P1(LoxP)/LoxP/Jnk2−/− (Hepatocyte-
specific knockout of Jnk1 [ JNK1Δhepa]) mice were 
created as reported.(13-15) We used male mice for all 
experiments. For in vivo experiments, mice were treated 
with a daily dose of lapatinib (150 mg/ kg weight; n = 7 
mice per group) or vehicle (0.5% hydroxypropylmethyl-
cellulose/1% Tween 80) (n = 6) by oral gavage starting 
at 6 weeks of age over a period of 6 weeks. For small 
interfering (si)RNA-mediated knockdown experiments, 
8-week-old nuclear factor kappa B (NF-κB) essential 
modulator (NEMO)Δhepa/JNK1Δhepa were injected 
with a dose of 0.2 mg/kg body weight (BW) siJnk2 or 
small interfering luciferase (siLuc) once per week over a 
period of 4 weeks. In parallel, lapatinib was given orally 
to siJnk2-treated NEMOΔhepa/JNK1Δhepa mice on the 
same day of the first siJnk2- injection. Induction of tum-
origenesis was performed by intraperitoneal injection of 
25  mg/kg BW of diethylnitrosamine (DEN; Sigma-
Aldrich, Munich, Germany) at 14  days of age. Mice 
were killed 24  weeks later. Vehicle-injected (saline) 
male mice served as controls.
Animal experiments were carried out according to 
the German legal requirements and animal protection 
law and approved by the authority for environment con-
servation and consumer protection of the state of North 
Rhine-Westfalia (LANUV; Germany). All strains were 
crossed on a C57BL/6 background. The mice were 
housed in the Institute of Laboratory Animal Science 
at the University Hospital RWTH-Aachen University 
according to German legal requirements (Animal 
Welfare Act [DeutschesTierschutzgesetz], Federation 
of European Laboratory Animal Science Associations 
[FELASA], Society of Laboratory Animal Science 
[GV-SOLAS]) under a permit of the Veterinäramt 
der Städteregion Aachen. All animals received humane 
care according to the criteria outlined in the Guide 
for the Care and Use of Animal Models. All organ 
explants and animal experiments were approved by the 
local authority for environment conservation and con-
sumer protection of LANUV on the following animal 
grants: 30034G (AZ-84-02.04.2016.A080) and TVA-
11324GZ (AZ-84-02.04.2016.A490).
inteRFeRenCe Rna against 
Jnk2 (siJnk2)
The siRNA molecules were purchased from Axolabs 
GmbH (Kulmbach, Germany) and were chosen due 
to their ability to specifically target Jnk2 in mice with 
mismatches to Jnk1 (2-18 nucleotides) to increase 
in vivo stability and suppression of the immune- 
stimulatory properties, as described.(16)
Data anD soFtWaRe 
aVailaBility
Affymetrix Microarray was performed as 
described,(17) and data were deposited with the 
National Center for Biotechnology Information Gene 
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Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE14 0498.
statistiCal analysis
All data are expressed as mean ± SEM. Statistical 
significance was determined by two-way analysis of 
variance (ANOVA) followed by a Student t test or by 
one-way ANOVA followed by a Newman-Keuls mul-
ticomparison test. P < 0.05 was considered significant.
Results
ComBineD loss oF Jnk1/2 
FunCtion in HepatoCytes 
tRiggeRs BiliaRy 
HypeRpRoliFeRation anD 
DuCto/Cystogenesis in an 
eXpeRimental moDel oF 
CHRoniC liVeR Disease
Mice lacking NEMO in LPCs spontaneously 
develop HCC, rendering these animals an ideal model 
that perfectly mimics progression of chronic liver disease 
(CLD) as observed in humans.(18) We previously estab-
lished that Jnk1 and Jnk2 have specific roles for the pro-
gression of NEMO∆hepa-dependent chronic liver injury, 
indicating that the MAPK genes expressed in liver cells 
have pivotal functions in cell death and inflammation.(19) 
We then found that combined activities of Jnk1 and 
Jnk2 specifically in hepatocytes protected against toxic 
liver injury (CCl4 and acetaminophen).
(15) However, 
Jnk1/2 deficiency in hepatocytes increased tumor bur-
den in an experimental model of HCC.(10) Therefore, in 
the present study we aimed to investigate the definitive 
contribution of JNK genes to liver cancer.
For this purpose, we generated NEMO∆hepa/
JNKΔhepa and their respective controls NEMO∆hepa and 
NEMOfloxed (f/f ) mice (Supporting Fig. S1) and exam-
ined the progression of liver disease. At 13 weeks of age, 
histologic evaluation of NEMO∆hepa unveiled the pres-
ence of dysplastic nodules, steatohepatitis, and cell death 
(Supporting Fig. S2A,B). All NEMO∆hepa/JNKΔhepa 
livers with no external signs of nodules spontaneously 
showed hyperproliferation of biliary epithelium trans-
lated into hepatic ducto/cystogenesis and lymphoid 
aggregates surrounding these structures (Supporting 
Fig. S2A,B).
Development of HCC is characteristic of 1-year-
old NEMOΔhepa mice, visible both macroscopi-
cally and histologically. However, most 52-week-old 
NEMO∆hepa/JNKΔhepa mice displayed no signs of 
HCC. Here, yellowish coloration of the liver paren-
chyma was associated with hyperproliferation of bil-
iary epithelial cells and lymphoid cell accumulation. 
This was much more pronounced than at earlier 
stages of CLD. Interestingly, histopathological exam-
ination of these specimens in two different institutes 
(Utrecht and Graz) revealed that approximately 33% 
of 52-week-old JNKΔhepa livers presented small cysts 
while an increased frequency and a higher number of 
ductular cells were evident in the hepatic parenchyma 
of all NEMO∆hepa/JNKΔhepa, with atypia compatible 
with CCA (Fig. 1A,B; Table 1).
Moreover, combined JNK1/JNK2 deletion in 
hepatocytes of NEMO∆hepa mice triggered signifi-
cantly reduced BW and liver weight (LW) compared 
with NEMO∆hepa mice but a similar LW/BW ratio as 
hepatocyte-specific NEMO-deficient mice (Fig. 1C). 
Notably, at 13  weeks of age, NEMO∆hepa/JNKΔhepa 
animals had a significantly increased hepatosomatic 
ratio compared with NEMO∆hepa mice, albeit no dif-
ferences in BW or LW (Supporting Fig. S2C).
Surprisingly, 1 year-old NEMO∆hepa/JNKΔhepa livers 
exhibited reduced HCC compared with NEMO∆hepa 
animals (Fig. 1D). In contrast, JNK1/2-deleted NEMO 
mice displayed ducto/cystogenesis that was much more 
pronounced than at earlier stages of CLD (Fig. 1B; 
Supporting Fig. S2D). NEMO∆hepa/JNKΔhepa livers 
exhibited significantly elevated glutamate dehydroge-
nase, total bilirubin, alkaline phosphatase,  aspartate 
aminotransferase (AST), and alanine aminotransferase 
(ALT) levels compared with NEMO∆hepa mice, already 
detectable at 13  weeks (Fig. 1D,E; Supporting Fig. 
S2D,E). Altogether, these data indicated that deletion 
of Jnk1/2 in an experimental model of CLD has piv-
otal implications in cell death, cholestasis development, 
and ductular proliferation of cholangiocytes.
analysis oF tHe 
miCRoenViRonment  
DRiVing massiVe Bile  
DuCt pRoliFeRation in 
nemo∆hepa/JnKΔhepa animals
Lack of NF-κB activity in hepatocytes trig-
gers  spontaneous HCC. In turn, 52-week-old 
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Fig. 1. Deletion of Jnk1/2 in 52-week-old NEMOΔhepa livers triggers cyst formation. (A) Macroscopic view of livers from 52-week-old 
NEMOf/f (wild type), NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice. (B) Representative H&E staining of liver sections of NEMOf/f, 
NEMOΔhepa, and NEMOΔhepa/JNKΔhepa livers at 52 weeks of age. Different magnifications were used (left). Scale bar 200 µm. Cyst 
frequency and number of visible microscopic cysts per 10× view field were calculated and graphed (right), magnification is 10× for upper 
and magnification is 20× for lower. (C) BW (left); LW (center); LW/BW ratio (right). (D) Tumor burden for each individual mouse 
was characterized by calculating total number of visible tumors >5 mm in diameter per mouse (left); serum levels of GLDH (center); 
bilirubin (right). (E) Serum levels of AP (left), AST (center), and ALT (right), in 52-week-old NEMOf/f, JNKΔhepa, NEMOΔhepa, and 
NEMOΔhepa/JNKΔhepa mice. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Abbreviations: AP, 
alkaline phosphatase; GLDH, glutamate dehydrogenase; H&E, hematoxylin and eosin.
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NEMO∆hepa/JNKΔhepa mice displayed significantly 
increased bile duct proliferation. We next investigated 
liver damage associated with the phenotype of these 
animals. We first applied terminal deoxynucleotidyl 
transferase–mediated deoxyuridine triphosphate nick-
end labeling (TUNEL) staining, which detects several 
types of cell death, including necrosis, apoptosis, and 
necroptosis.(20) NEMO∆hepa livers displayed a high per-
centage of TUNEL-positive cells, while NEMO∆hepa/
JNKΔhepa livers showed significantly increased levels of 
cell death (Fig. 2A).
Apoptosis and necroptosis are two relevant forms of 
cell death in the pathogenesis of human and murine 
liver disease.(21,22) To discriminate between these two 
types of cell death, we performed immunohistochemis-
try (IHC) analyses, which revealed significantly higher 
levels of the apoptosis marker cleaved caspase 3 (CC3) 
in NEMO∆hepa/JNKΔhepa livers, especially in cholan-
giocytes but also in immune infiltrates of these livers 
(Fig. 2B). We subsequently studied proteins involved 
in necroptosis, e.g., receptor-interacting serine/ 
threonine-protein kinase 3 (RIPK3) by western blot and 
IHC, which was found overexpressed in NEMO∆hepa/
JNKΔhepa livers, while no difference in RIPK1 protein 
expression was found (Fig. 2E; Supporting Fig. S3A).
Cell-cycle dysregulation is characteristic of biliary 
overgrowth, resulting in CCA. Increased Ki-67-positive 
and proliferating cell nuclear antigen (PCNA)-positive 
cells were observed in NEMO∆hepa/JNKΔhepa frozen 
and paraffin sections, respectively, the latter further con-
firmed by immunoblot analysis (Fig. 2C,E; Supporting 
Fig. S3B). Moreover, the number of transcripts for 
PCNA and cyclin D1 was up-regulated in NEMO∆hepa/
JNKΔhepa livers (Supporting Fig. S3C). P21 has been 
shown to induce cell-cycle arrest and promote the DNA 
repair gene, thus acting as a tumor suppressor.(23,24) 
Interestingly, we observed p21 overexpression in Jnk1/2-
deficient NEMO∆hepa mice (Fig. 3E). Moreover, oxida-
tive stress in the liver microenvironment has a definitive 
role in CCA development. We thus measured lipid per-
oxidation and the antioxidant defense of these animals. 
Interestingly, strong 4-hydroxynonena immunostain-
ing and catalase depletion (Supporting Fig. S3D,E) in 
NEMO∆hepa/JNKΔhepa livers confirmed elevated reac-
tive oxygen species (ROS) production associated with 
cholangiocellular proliferation.
Hepatic stellate cells (HSCs) are important cells 
shaping the hepatic microenvironment after liver dam-
age. Hence, HSCs are involved in the high number of 
α-smooth muscle actin (α-SMA)-positive myofibro-
blasts and extracellular matrix (ECM) deposition associ-
ated with CCA development.(25) Sirius red staining and 
quantification confirmed strong collagen deposition in 
NEMO∆hepa/JNKΔhepa livers (Fig. 2D; Supporting Fig. 
S4A). Furthermore, collagen type I alpha 1 (Col1A1) 
and α-SMA were dramatically overexpressed in 
NEMO∆hepa/JNKΔhepa liver protein lysates (Fig. 2E) and 
were associated with significantly increased transcripts of 
col IA1, matrix metalloproteinase (mmp)7/9/12, and tissue 
inhibitor of metalloproteinase (timp)1 (Supporting Fig. 
S4B,C). Cytokine-mediated tissue fibrosis was also mea-
sured, and levels of monocyte chemoattractant protein 
1 (mcp1), tumor necrosis factor (tnf  ), interleukin (il)1β, 
and regulated upon activation, normal T cell expressed, 
and secreted (rantes) were significantly up-regulated in 
NEMO∆hepa/JNKΔhepa mice (Supporting Fig. S4D,E). 
Altogether, these data suggest that fibrogenesis and 
unresolved inflammation are involved in CCA develop-
ment in the NEMO∆hepa/JNKΔhepa context while HCC-
related tumorigenesis is diminished as confirmed by low 
glutamine synthase expression (Supporting Fig. S5A).
nemo∆hepa/JnKΔhepa liVeRs 
eXHiBit typiCal FeatuRes oF 
Human CCa
Immunohistochemical analysis revealed that 
many ductules were composed of creatine kinase 
taBle 1. HistopatHologiCal 
CHaRaCteRistiCs oF tHe DiFFeRent mouse 
gRoups (sCale, 0-4)
NEMO∆hepa NEMO∆hepa/JNKΔhepa
Neoplasia HCC Cystic cholangioma 
Mucinous CCA
Anisokaryosis 3.5 2.0
Altered foci 2.0 1.8
Mitosis/HPF (40×) 2.5 1.0
Cellular hypertrophy 3.0 2.5
Dysplasia 3.0 2.5
Oval cell proliferation 1.5 2.5
Portal inflammation 1.0 1.0
Overall inflammation 3.0 3.5
Ductular reaction 1.5 2.0
Apoptosis 1.0 3.0
Fibrosis 3.0 4.0
Steatosis 1.4 0.0
Others Pale cytoplasm 
hepatocytes
Massive bile duct 
proliferation
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Fig. 2. Characterization of cell death, cell proliferation, and collagen deposition in 52-week-old NEMOΔhepa/JNKΔhepa mice. 
(A) Representative TUNEL staining of liver sections of NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa livers at 52 weeks of age 
(left). TUNEL-positive cells were quantified and graphed (right). (B) Representative IHC staining for CC3 of the same livers (left). 
CC3-positive cells were quantified and graphed (right). (C) Immunofluorescent staining for Ki-67 of liver cryosections from the same 
livers (left). Ki-67-positive cells were quantified and graphed (right). (D) Representative sirius red staining of paraffin sections from the 
indicated genotypes (left). Quantification of the positive sirius red area fraction was performed with Image J and graphed (right). (A-D) 
Scale bars, 200 μm. Arrows (→) indicate positive cells. Data are presented as mean ± SEM; ****P < 0.0001. (E) Protein levels of α-SMA, 
Col1A1, PCNA, p21, RIPK1, and RIPK3 from whole-liver extracts of 52-week-old NEMOf/f, JNKΔhepa, NEMOΔhepa, and NEMOΔhepa/
JNKΔhepa mice were analyzed by western blot with the indicated antibodies. GAPDH was used as a loading control.
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(CK)19-positive cells. In fact, NEMO∆hepa/JNKΔhepa 
cystic and CCA-like structures exhibited CK19-
positive staining that was corroborated by dramatically 
elevated CK7/19 messenger RNA (mRNA) expres-
sion in these livers (Fig. 3A,D). NEMOf/f had regular 
small bile ducts, and NEMO∆hepa exhibited mild to 
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moderate ductular proliferates similar to a ductular 
reaction in humans. Noticeably, livers of NEMO∆hepa/
JNKΔhepa mice displayed cholangiocellular proliferates 
with a tubular architecture resembling the morphology 
of human well-differentiated CCA, highlighted by a 
strong-positive CK19 signal. In contrast, hepatocyte 
nuclear factor (HNF)-4α staining was characteristic 
of pericystic areas and hepatocytes of NEMO∆hepa 
and NEMOf/f livers (Fig. 3B). Cells containing 
cytoplasmic mucin (MUC) granules are common in 
CCA tissues.(26) Thus, we assessed the expression 
of MUC1 and MUC5AC, which are closely related 
to dedifferentiation, infiltrative growth pattern, and 
patient survival.(26) Whereas MUC1 staining was 
limited to areas of ductogenesis or oval cell reaction 
in NEMO∆hepa livers, it was very strong in cysts of 
NEMO∆hepa/JNKΔhepa livers, which were associated 
with significantly increased muc1 and muc5ac mRNA 
levels in these mice (Fig. 3C,D).
High expression of cholangiocyte markers, includ-
ing cluster of differentiation (cd)133 and expression of 
CCA/tumor-enriched markers, including epithelial cell 
adhesion molecule (epcam), deleted in malignant brain 
tumors 1 (dmbt1), and gamma-aminobutyric acid A 
receptor, pi (gabrp),(27) together with the accumulation 
of transcription factor SOX 9 (SOX-9)-positive cells 
(Fig. 3E,F; Supporting Fig. S5B) suggest that loss of 
Jnk1/2 function in hepatocytes promotes the shift from 
HCC to CCA in this experimental model of CLD.
aDministRation oF Den to 
JnKΔhepa miCe tRiggeRs HepatiC 
DuCto/Cystogenesis WitHout 
HepatoCaRCinogenesis
To validate the relevance of Jnk1/2 in mediating 
the shift from HCC to CCA, we applied a second 
model of carcinogenesis, the DEN model. Previously, 
Das and colleagues,(10) using mice with compound 
deficiency of Jnk1/2 in hepatocytes, demonstrated 
that the JNK genes possess tumor-suppressing roles 
in liver carcinogenesis that depend on the cell types 
of the liver. Additionally, we showed that hepatocyte- 
specific Jnk1/2 knockout female and male mice have 
no phenotype affecting the correct function of the 
liver.(15) These previous results are confirmed in the 
present study in a larger pool of animals ranging 
from 13 to 52 weeks of age (Supporting Figs. S6A-D 
and S7A-D). However, approximately 33% of these 
mice from week 30 of age histologically displayed 
tumors resembling human CCA in their liver paren-
chyma that did not affect liver function (Fig. 1A,B; 
Supporting Fig. S7A-D).
JNKΔhepa mice were challenged with the carcinogen 
DEN. Interestingly, these mice exhibited jaundice and 
the liver was yellowish albeit with decreased tumor 
load (Supporting Fig. S8A). The LW/BW ratio 
was significantly decreased in JNKΔhepa compared 
with JNKf/f mice (Supporting Fig. S8B). Histologic 
evaluation performed by two blinded patholo-
gists demonstrated the presence of cystogenesis and 
cholangioma-like structures in liver parenchyma 
accompanied by strong infiltration of immune cells 
(Fig. S8C). The analysis of serum transaminases in 
JNKΔhepa demonstrated decreased ALT and AST 
 levels in these animals (Fig. S8D,E). These results 
indicated that JNK1 and JNK2 might influence cell 
fate during liver tumorigenesis.
To further analyze the differences between both 
animal models, age progression versus chemically 
induced HCC, we performed a microarray analysis 
(Supporting Fig. S9A,B). Interestingly, dmbt1, muc1, 
gabrp, and immunoglobulin heavy chain (gamma 
polypeptide) (ighg)2b were commonly up-regulated 
in Jnk1/2-deficient NEMO∆hepa mice and Jnk1/2-
deficient mice challenged with DEN, indicating that 
epithelial–mesenchymal transition (EMT) might be 
modulated through a JNK-dependent mechanism.
Fig. 3. Loss of Jnk1/2 in NEMOΔhepa hepatocytes triggers cholangiocellular proliferation. (A) Representative IF for CK19 of liver 
cryosections was performed in 52-week-old NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa livers (upper panel). IHC staining 
for CK19 reveals densely packed cholangiocellular proliferates with a tubular growth pattern mimicking morphologic features of well-
differentiated human CCA (lower panel), magnification is 20×. (B) Representative IF staining for HNF-4α of the same livers, magnification 
is 20×. (C) Representative IHC staining for Muc1, magnification is 20×. (D) mRNA expression analysis of CK7 (left), CK19, and muc1 
(center) and muc5ac (right) was quantified by qRT-PCR in the same livers. (E) mRNA expression analysis of Epcam (left), CD133 and 
DMBT1 (center), and GABRP (right) was quantified by qRT-PCR of samples taken from NEMOf/f, NEMOΔhepa, and NEMOΔhepa/
JNKΔhepa livers killed at 52 weeks. (F) Protein expressions of GABRP and DMBT1 from whole-liver extracts of 52-week-old NEMOf/f, 
JNKΔhepa, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice were analyzed by western blot with the indicated antibodies. GAPDH served 
as loading control. Data are presented as mean ± SEM. *P < 0.05; ****P < 0.0001. Abbreviations: CD, cluster of differentiation; Epcam, 
epithelial cell adhesion molecule; IF, immunofluorescence.
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Next, we analyzed total common up-regulated 
and down-regulated genes in NEMOΔhepa/JNKΔhepa 
versus JNKΔhepa  +  DEN, which were the majority 
compared to specific changes of each experimental 
model (Supporting Fig. S9C,D). Heat map anal-
ysis of these genes showed up-regulation of genes 
related to CCA, like dmbt1, muc1, gabrp, and matrix 
deposition, including timp1 and mmp12, and down- 
regulation of serpines, which are often implicated in 
HCC development (Fig. 4A). Altogether, these data 
reinforce the notion that the JNK signaling pathway 
modulates cell fate during liver carcinogenesis.
oVeReXpRession oF tHe  
il-6/signal tRansDuCeR anD 
aCtiVatoR oF tRansCRiption 
3 patHWay is CHaRaCteRistiC 
FoR nemo∆hepa/JnKΔhepa liVeRs
Cytokines play an important role during carcinogen-
esis by shaping the inflammatory microenvironment 
toward malignant transformation.  In particular, IL-6 
has been demonstrated to have an integral role in CCA 
biology and other cancers as a growth and survival fac-
tor.(28) Under physiologic conditions, IL-6 through a 
Janus kinase ( JAK)/signal transducer and activator of 
transcription (STAT) 3 pathway induces expression of 
suppressor of cytokine signaling 3 (SOCS3), acceler-
ating inflammation, cell growth, and tumor formation. 
We found overexpression of il6, il6 receptor (il6r), and 
socs3 mRNA as well as other IL-6 family members, 
including LIF IL-6 family cytokine (lif) and oncosta-
tin M (osm) (Fig. 4B,C; Supporting Fig. S10A). OSM 
has recently been identified as an important regulator 
of the EMT/cancer stem cell plasticity program that 
promotes tumorigenic properties.(29) Osm was signifi-
cantly increased in NEMO∆hepa/JNKΔhepa livers.
Concomitantly, high phosphorylated STAT3 
(pSTAT3) levels were evident in NEMO∆hepa/
JNKΔhepa compared with NEMO∆hepa livers (Fig. 4D; 
Supporting Fig. S10B), indicating that this pathway is 
strongly activated in our murine model.
tHe egF-Raf-meK-eRK1/2 
patHWay is oVeReXpResseD in 
nemo∆hepa/JnKΔhepa animals
Activation of Notch and Wnt signaling pathways 
stimulates proliferation of the hepatic progenitor 
cell compartment. In particular, NOTCH signaling 
is implicated in the commitment toward the chol-
angiocyte fate, while WNT can trigger differenti-
ation toward the hepatocyte lineage.(30) Therefore, 
we first assessed the relevance of Notch-1 (A6) 
in NEMO∆hepa/JNKΔhepa livers. Interestingly, A6 
staining was positive in clusters of immune cells in 
NEMO∆hepa livers. NEMO∆hepa/JNKΔhepa livers 
exhibited increased Notch-1 expression throughout 
the liver parenchyma (Fig. 5A). In fact, other family 
members, including Notch2, were significantly up- 
regulated or had a tendency toward increased mRNA 
levels in NEMO∆hepa/JNKΔhepa livers (Fig. 5C; 
Supporting Fig. S11A-F). However, no differences 
in β-catenin expression between NEMO∆hepa and 
NEMO∆hepa/JNKΔhepa livers were observed (Fig. 5D). 
Of note, JNK1/2-knockout mice had reduced phos-
phorylation of β-catenin, indicating that JNK is nec-
essary for β-catenin phosphorylation, as suggested.(31)
The epidermal growth factor receptor (EGFR) 
family includes erythroblastic oncogene B (ERBB)1, 
2, 3, and 4, with ERBB1/EGFR and ERBB2/human 
epidermal growth factor receptor 2 (HER2) (Neu in 
rodents) being frequently implicated in the multi-
step carcinogenesis of CCA.(32) Specifically, HER2 
is a well-described predictive biomarker for positive 
anti-HER2 therapy response in breast and gastric 
cancer and, lately, in CCA.(33,34) Our first results 
showed dramatically increased ErbB2 protein and 
mRNA levels in livers of NEMO∆hepa/JNKΔhepa com-
pared with NEMO∆hepa hepatic tissue (Fig. 5B-D). 
Interestingly, we also found increased expression of 
the EGFR ligand egf (Fig. 5C). Consistently, the 
levels of EGFR phosphorylation (pEGFR) were 
markedly elevated in the livers of NEMO∆hepa/
JNKΔhepa mice (Fig. 5D).
The rapidly accelerated fibrosarcoma (RAF)-
mitogen-activated protein kinase kinase (MEK)- 
extracellular signal-regulated kinase (ERK)  trans-
duction pathway is a key signaling cascade that 
regulates cellular proliferation, differentiation, and 
apoptosis and is frequently dysregulated in HCC(35) 
and in biliary tract cancer.(36) Binding of  EGF to 
EGFR triggers its tyrosine kinase activity down-
stream signaling leading to the end phosphoryla-
tion of  MEK1/2 and  ERK1/2, with translocation 
of ERK to the nucleus and expression of genes 
related to proliferation.  Increased phosphorylation 
(i.e., activation) of RAF, MEK1/2, and ERK/2 was 
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found in NEMO∆hepa/JNKΔhepa mice (Fig. 5D) asso-
ciated with biliary overgrowth. These results were 
further corroborated in livers of 13-week-old mice 
(Supporting Fig. S12), indicating that the RAF-
MEK-ERK pathway was constitutively activated at 
early stages of cholangiocarcinogenesis.
A
B
C
D
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lapatiniB tReatment 
pReVents BiliaRy eXpansion 
anD DuCto/Cystogenesis in 
nemo∆hepa/JnKΔhepa miCe
Our data strongly indicate the EGFR-HER2 path-
way being involved in biliary cell hypergrowth and 
cholangiocarcinogenesis in NEMO∆hepa/JNKΔhepa 
livers. Lapatinib is a dual EGFR2/HER2 tyrosine 
kinase inhibitor (TKI) targeting both EGFR and 
HER2.(37,38) It successfully inhibited the growth of 
HER-overexpressing breast cancer cells in culture and 
in tumor xenografts.(39) Taking into consideration the 
promising therapeutic option of lapatinib, we subse-
quently explored the potential beneficial effect of this 
dual TKI in our model of cholangiocellular proliferation.
Lapatinib was administered daily by oral gavage for 
6 weeks in NEMOf/f, NEMO∆hepa, and NEMO∆hepa/
JNKΔhepa mice (Fig. 6A). The TKI did not cause any 
relevant histopathological or serum biochemistry alter-
ations to NEMOf/f or NEMO∆hepa animals (Fig. 6B). 
However, lapatinib treatment of NEMO∆hepa/
JNKΔhepa mice resulted in a significant reduction 
of cyst-like structures (Fig. 6B). Lapatinib also sig-
nificantly reduced serum AST and ALT levels in 
NEMO∆hepa/JNKΔhepa compared with NEMOf/f and 
NEMO∆hepa animals (Fig. 6C).
Next, the impact of lapatinib on EGFR/HER2 
signaling was tested by investigating the downstream 
RAF-MEK-ERK pathway below EGFR/HER2. 
Decreased activation of EGFR and abrogation of 
RAF, MEK, and ERK signaling pathways were found 
in lapatinib-treated livers compared with vehicle- 
administrated NEMO∆hepa/JNKΔhepa livers (Fig. 6D). 
These results suggest that lapatinib successfully 
decreases EGFR-HER2 signaling and functionally 
links inhibition of this pathway with biliary over-
growth in NEMO∆hepa/JNKΔhepa livers.
ComBineD JnK1/JnK2 
Deletion is essential FoR 
HypeRpRoliFeRation oF Bile 
DuCts
Our data were generated in global JNK2−/− mice. 
Hence, we aimed to distinguish if hepatocytic or 
nonparenchymal JNK2 function is essential to direct 
bile duct proliferation. We applied our recently devel-
oped hepatocyte-specific Jnk2 siRNA (siJnk2) pro-
tocol using lipid nanoparticles(16); siLuc served as 
controls. We included 6- to 8-week-old untreated 
floxed NEMOf/f/JNKf/f, siLuc-treated NEMO∆hepa/
JNK1Δhepa, and siJnk2-challenged NEMO∆hepa/
JNK1Δhepa mice in this analysis. In parallel, animals 
were treated with vehicle or lapatinib.
Interestingly, Jnk2 knockdown in hepatocytes trig-
gered massive biliary cyst formation in livers of vehicle- 
treated NEMO∆hepa/JNK1Δhepa animals compared 
with siLuc-NEMO∆hepa/JNK1Δhepa and untreated 
floxed NEMOf/f/JNKf/f mice (Supporting Fig. S13A). 
These results demonstrate that combined Jnk1/2 dele-
tion in hepatocytes is responsible for directing biliary 
hyperproliferation in this model. Additionally, lapati-
nib treatment successfully reduced liver cystogenesis 
and significantly ameliorated serum transaminases in 
NEMO∆hepa/JNK1Δhepa + siJnk2 livers, confirming the 
efficacy of this TKI in experimental biliary cystogen-
esis (Supporting Fig. S13B-D).
Discussion
Hyperplasia of the biliary epithelia with variable 
atypia in cystic bile ducts may give rise to malig-
nant transformation leading to intrahepatic CCA for 
which an enormous unmet clinical and research need 
exists. CCA is an epithelial neoplasm derived from 
Fig. 4. The IL-6/STAT3 pathway is pivotal in biliary cell proliferation during liver carcinogenesis. (A) Gene array analysis was performed 
in 8-week-old NEMOΔhepa/JNKf/f and NEMOΔhepa/JNKΔhepa livers in addition to 26-week-old wild type and JNKf/f and JNKΔhepa livers 
challenged with DEN. Correlation of the fold induction of gene expression in liver is shown. Log2 expression values of the individual 
mice were divided by the mean of the NEMOΔhepa/JNKΔhepa mice. Log ratios were saved in a .txt file and analyzed with the Multiple 
Experiment Viewer. Top up-regulated and down-regulated target substrates are shown (red, up-regulated; green, down-regulated; n = 3, 
3.0< fold change >3.0). (B) mRNA expression analysis of il6 (left); il6r (center), and socs3 (right). (C) mRNA expression analysis of osm 
(left), osmr (center), and lif (right) was quantified by qRT-PCR of samples taken from NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa 
livers killed at 52  weeks. (D) Protein expression levels of STAT3 and pSTAT3 from whole-liver extracts of 52-week-old NEMOf/f, 
JNKΔhepa, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice were analyzed by western blot with the indicated antibodies. GAPDH served 
as loading control. Abbreviations: DKO, JNK1f/f/JNK2−/− + DEN; LIF, leukemia inhibitory factor; osmr, oncostatin M receptor; TKO, 
NEMOΔhepa/JNKΔhepa.
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Fig. 5. Activation of EGF-EGFR-RAF-MEK1/2-ERK1/2 is distinctive of NEMOΔhepa/JNKΔhepa mice. (A) Representative IHC for 
NOTCH-1 staining of liver sections of 52-week-old NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa livers, magnification is 20×. 
(B) Representative IHC for ErbB2 staining of liver sections of the same livers. (C) mRNA expression analysis of notch-2 (left), erbB2 
(center), and egf (right) was quantified by qRT-PCR of samples taken from NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice 
killed at 52 weeks. Data are presented as mean ± SEM. *P < 0.05; ****P < 0.0001. (D) Protein expressions of phospho-β-catenin, β-catenin, 
ErbB2, phospho-EGFR, phospho-RAF, phospho-MEK1/2, phospho-ERK1/2, and total ERK1/2 from whole-liver extracts of 52-week-
old NEMOf/f, JNK1Δhepa/JNK2−/−, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice were analyzed by western blot with the indicated 
antibodies. GAPDH served as loading control. Abbreviation: phospho, phosphorylated.
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primary and secondary bile tracts and accounts for 
5%-10% of primary liver cancer, the incidence and 
mortality of which are steadily increasing. The 5-year 
survival of patients with CCA remains unacceptably 
low, and survival has not dramatically improved in 
the past 20  years.(40) This is in part due to a lack of 
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understanding of the pathophysiologic mechanisms 
underlying CCA. Because biliary tract cancer is often 
diagnosed late, the success of the only curative pro-
cedure (surgical resection) is limited, and the lack of 
biomarkers or diagnostic tools that would lead to early 
diagnosis is a matter of concern.(41)
A recent study(12) opened a Pandora´s box for ther-
apeutic options targeting the JNK signaling pathway, 
a major regulator of cell proliferation, against CCA. 
Earlier, several studies confirmed the critical role of 
the JNK signaling pathway in liver cancer.(10,19,42-44) 
At present, little is known on the role of JNK in direct-
ing differentiation of LPCs and more specifically of 
bipotential hepatic cells not only in liver homeostasis 
but also following liver injury.
We first focused on the specific roles of the Jnk 
genes in the progression of experimental chronic liver 
disease using NEMO mice and showed how Jnk1 
or Jnk2 tipped the balance toward HCC or necro-
inflammation, respectively.(19) We later demonstrated 
that combined Jnk1/2 deletion in hepatocytes triggers 
more severe liver injury, inflammation, and progres-
sion after toxic liver injury.(15)
Thus, we next sought to investigate the conse-
quences of hepatocytic Jnk1/2 ablation in liver paren-
chymal proliferation and growth in experimental HCC. 
For this purpose, we generated NEMO∆hepa/JNKΔhepa 
mice, which displayed reduced tumor burden, despite 
the fact that they had signs of jaundice and hyper-
bilirubinemia, compared to NEMO-deficient mice 
developing HCC.(18) Remarkably, Jnk1/2-deleted 
NEMO∆hepa livers exhibited hyperproliferation of 
the biliary epithelium, forming cyst-like structures 
compatible with cholangioma or malignant CCA, as 
assessed by two independent pathologists (Table 1).
These livers were characterized by cell death, 
inflammatory microenvironment, and ECM deposi-
tion. Necroptosis-associated hepatic cytokine micro-
environment induces the shift from HCC to CCA 
development.(22) NEMO∆hepa/JNKΔhepa livers display 
considerable CC3 staining and RIPK3 protein levels, 
triggering exacerbated compensatory proliferation of 
LPCs, which are associated with increased ROS pro-
duction and failure of the antioxidant defense.
Moreover, deposition of ECM and periductural/
pericystic scar formation was a prominent feature 
in NEMO∆hepa/JNKΔhepa livers. A unique charac-
teristic of CCA is the presence of cancer-associated 
fibroblasts (CAFs) surrounded by numerous immune 
cells.(41) CAFs promote the secretion of chemokines/ 
cytokines including EGF in CCA cell lines.(45) 
Moreover, TNF might be another important culprit 
in CCA development, as suggested.(12)
In parallel with proliferating hepatocytes and 
a marked expansion of the biliary epithelium, the 
liver parenchyma of NEMO∆hepa/JNKΔhepa animals 
was positive for CK19 and SOX-9 and negative for 
HNF-4α. Moreover, we found increased expression 
of mucin genes. Considering that CCA tissues are 
characterized by the presence of mucin-secreting cells, 
this finding further supports the CCA diagnosis.(46) 
Interestingly, analysis of gene expression showed the 
occurrence of CCA/epithelial-transformed neoplasia- 
enriched markers, including Dmbt1 and Gabrp, not 
only in NEMO∆hepa/JNKΔhepa liver but also in a sec-
ond model of liver carcinogenesis, the DEN model. 
Confirmation in the two models suggests that CCA 
development relies on Jnk1/2 combined function in 
hepatocytes but is independent of NF-κB activity in 
LPCs. Moreover, microarray studies highlighted the 
pivotal role of Jnk1/2 in modulating cell fate by pro-
moting hepatocarcinogenesis and under-regulating 
cascades linked with cholangiocarcinogenesis. Our 
data undoubtedly indicate that loss of Jnk1/2 func-
tion promoted CCA in both experimental CLD and 
chemically induced HCC.
Jnk1/2-deleted NEMO livers exhibited strong 
expression of NOTCH-1/A6 and Notch-2 and a clear 
tendency toward increased expression of Notch sig-
naling pathway effectors. These results are consistent 
Fig. 6. Lapatinib, a dual tyrosine kinase inhibitor, protects against hyperbiliary proliferation in 52-week-old NEMOΔhepa/JNKΔhepa 
animals. (A) Experimental design of lapatinib (150 mg/kg BW) or vehicle administration to 6-week-old NEMOf/f, NEMOΔhepa, and 
NEMOΔhepa/JNKΔhepa mice. (B) Representative H&E staining of liver sections of NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa 
livers treated with either vehicle or lapatinib for 6 weeks (left), magnification is 10×. Number of visible microscopic cysts per 10× view 
field were calculated and graphed (right). (C) Serum levels of AST and ALT, in NEMOf/f, NEMOΔhepa, and NEMOΔhepa/JNKΔhepa mice 
after 6 weeks of lapatinib treatment. Data are presented as mean ± SEM. *P < 0.05, ***P < 0.001, #P < 0.05 (intergroup). (D) Levels of 
phospho-ERK1/2, phospho-MEK1/2, phospho-RAF, and phospho-EGFR from whole-liver extracts of the indicated genotypes treated 
with vehicle or lapatinib were analyzed by western blot with the indicated antibodies. GAPDH served as loading control. Abbreviations: 
H&E, hematoxylin and eosin; phospho, phosphorylated.
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with evidence from mouse studies, suggesting that 
NOTCH and WNT/β-catenin are key drivers of CCA 
development. Specifically, NOTCH-1, -2, and -3 were 
shown to be overexpressed in human cholangiocellu-
lar injury.(47) In contrast, no differences in β-catenin 
expression between NEMO∆hepa and NEMO∆hepa/
JNK∆hepa were observed, indicating that hepatocyte 
differentiation in our model is inhibited in favor of 
ductular reaction and cholangiocyte differentiation. Of 
note, JNK1/2-knockout mice have reduced phosphor-
ylation of β-catenin, suggesting that JNK is necessary 
for β-catenin phosphorylation, as suggested.(31)
Our protein and mRNA data overwhelmingly 
indicated that overexpression and activation of the 
EGFR/ErbB2 family was implicated in multistep 
cystogenesis toward CCA in NEMO∆hepa/JNKΔhepa 
livers. Indeed, EGFR  overexpression occurs in 11%-
27% of human CCA, whereas HER2 overexpression 
is less frequent but very characteristic in transgenic 
mouse models.(36,48) It has been reported that EGF is 
released by tumor-associated macrophages (TAM).(49) 
Binding of EGF to its receptors induces their homod-
imerization or heterodimerization, which in turn acti-
vates downstream signaling pathways that regulate 
cell differentiation, migration, angiogenesis, and sur-
vival.(50) In our study, we specifically focused on RAF-
MEK1/2-ERK2 and JAK/STAT signaling. Both 
pathways were dramatically induced in NEMO∆hepa/
JNKΔhepa livers, suggestive of the strong prolifera-
tive and inflammatory microenvironment within the 
hepatic parenchyma.
Therefore, we tested the possibility of blocking 
EGFR/HER2 signaling as a novel strategy in treating 
hyperproliferation of the biliary epithelium. We used 
lapatinib, a dual TKI that efficiently inhibits both 
EGFR and HER2. Treatment not only prevented 
RAF-MEK-ERK activation but also inhibited biliary 
cyst formation. However, its efficacy in clinical trans-
lation may highly depend on enrollment of patients 
with EGFR/HER2 hyperactivation or overexpression.
Recently, Heikenwalder’s group showed the ther-
apeutic relevance of inhibiting JNK in CCA both 
in vivo and in cell lines.(12) LPC-specific Jnk1/2 
knockout mice were used in two different CCA mod-
els. In contrast to our observations, they found reduced 
cholangiocellular injury in both models. This apparent 
discrepancy between both studies may be reconciled 
considering that adeno-associated virus-mediated Cre 
expression in hepatocytes might not exactly resemble 
Alb-Cre excision since birth, as employed in our study. 
To further confirm the implications of Jnk1/2 abla-
tion in hepatocytes, we blocked Jnk2 specifically in 
hepatocytes using a liposome-delivery system coupled 
to an siRNA that was recently reported by our labo-
ratory.(16) Our data undoubtedly indicated that Jnk1/2 
in hepatocytes prevents biliary cell hyperproliferation. 
In addition, lapatinib successfully prevented activation 
of the EGFR-RAF-MEK1/2-ERK1/2 pathway in 
Jnk1/2 mice. However, more studies (e.g, assessment 
of JNK levels in vitro and in organoids) need to be 
performed to better define the specific role of JNK for 
CCA initiation.
Overall, our results show that complete inhibition 
of JNK signaling in hepatocytes in an experimental 
HCC model triggers binding of EGF (most likely 
released by the increased TAM-derived environment) 
to its receptor activating EGFR-RAF-MEK1/2-
ERK1/2 signaling. This cascade is essential to drive 
EMT transdifferentiation of oval cells into biliary 
cells and massive ducto/cystogenesis, which shares 
the molecular features of CCA. Here, CAF-derived 
cytokines, including tnf or transforming growth factor 
beta (tgfβ), might further contribute to exacerbated 
proliferation of biliary cells (Supporting Fig. S14).
Our study better delineates the pathogenesis of 
CCA by describing a novel function of JNK in chol-
angiocyte hyperproliferation. It also defines new 
therapeutic options to inhibit pathways involved in 
cholangiocarcinogenesis.
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